GlassScriptPhysician profile
John P Bader
NPI 1124588413
$1,183.18
in general payments reported to CMS, 2019-2025
10 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.99 · 2021: $155 · 2022: $309 · 2023: $238 · 2024: $244 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $618.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $358.14 | 2021-2022 | |
| Abbvie INC. | $264.56 | 2023-2025 | Alphagan P, Lumigan |
| Sight Sciences, INC. | $145.08 | 2023 | Omni Surgical System |
| Rayner Intraocular Lenses Limited | $135.29 | 2023-2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Genentech, INC. | $106.66 | 2022 | |
| Allergan, INC. | $99.99 | 2020 | |
| Harrow Eye, LLC | $28.89 | 2024 | Iheezo |
| E.R. Squibb & Sons, L.L.C. | $16.40 | 2025 | Reblozyl |
| Bausch & Lomb Americas INC. | $14.51 | 2025 | Miebo, Xiidra |
| Glaxosmithkline, LLC. | $13.66 | 2025 | Blenrep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.